These medications are employed in clinical settings to manage autoimmune diseases like psoriasis and rheumatoid arthritis (RA), wherein genetic abnormalities or modified posttranslational variations of the CTLA-4 gene or its promoter are detected. This evidence concerns the gene CTLA4 and rheumatoid arthritis.